Journal
JOURNAL OF CLINICAL MEDICINE
Volume 9, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/jcm9040921
Keywords
SABA overuse; systemic steroid overuse; asthma control; mild asthma; ICS adherence; treatment; exacerbation
Categories
Funding
- AstraZeneca Canada Inc.
Ask authors/readers for more resources
For years, standard asthma treatment has included short acting beta agonists (SABA), including as monotherapy in patients with mild asthma symptoms. In the Global Initiative for Asthma 2019 strategy for the management of asthma, the authors recommended a significant departure from the traditional treatments. Short acting beta agonists (SABAs) are no longer recommended as the preferred reliever for patients when they are symptomatic and should not be used at all as monotherapy because of significant safety concerns and poor outcomes. Instead, the more appropriate course is the use of a combined inhaled corticosteroid-fast acting beta agonist as a reliever. This paper discusses the issues associated with the use of SABA, the reasons that patients over-use SABA, difficulties that can be expected in overcoming SABA over-reliance in patients, and our evolving understanding of the use of anti-inflammatory relievers in our patients with asthma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available